The prevalence of rheumatic immune-related adverse events in 524 patients with cancer who received immune checkpoint inhibitors was 6.6%, according to a single-center observational study published in Annals of the Rheumatic Diseases.
Pointing to the potential usefulness of genetic tests and therapeutics in patient care, the American Medical Association is calling for greater transparency and more standardized guidelines for payer coverage.
A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.
A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter.
Debulking metastases of pancreatic neuroendocrine tumors may be effective at a threshold of greater than or equal to 70%, indicating that liver debulking criteria could possibly be extended to this threshold.
In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer.
The Blue Cross Blue Shield Association has announced a partnership with a Google-affiliated company to provide personalized type 2 diabetes care to members of its health plans.
A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer.
A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.
Data from the National Cancer Database, which is heavily dependent on institutional reporting, could be misleading about the burden of sarcomas in the United States.